Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...
Seeking Alpha on MSN20h
Viking phase 2b study of NASH candidate hits primary endpointA phase 2b trial of Viking Therapeutics' (NASDAQ:VKTX) VK2809 found that those on the medicine saw statistically significant ...
Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...
William Blair has the equivalent of a buy rating on the stock, as do all 13 analysts offering coverage of the stock on FactSet. The bank is one of many expecting Viking to be a takeover target, given ...
Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective ...
Dolby Laboratories (NYSE: DLB) rose 11% after it reported fourth quarter results that beat analysts' estimates on the bottom line. On a non-GAAP basis, f ...
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone ...
Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...
Viking's leading candidate isn't the only reason to consider the stock. The company's VK2809 is a promising potential treatment for metabolic dysfunction-associated steatohepatitis, a liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback